MK-8527 for Healthy Subjects

Overseen By Study Coordinator

Age: 18 - 65

Sex: Male

Trial Phase: Phase 1

Sponsor: Merck Sharp & Dohme LLC

Disqualifiers: Cancer, Hepatitis B, Hepatitis C, HIV

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 1

Duration: 1 day

8 Participants Needed

Trial Summary

Do I have to stop taking my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators.

What is the purpose of this trial?

The goal of this study is to learn how \[14C\]MK-8527 moves through a healthy person's body over time. Researchers will study how \[14C\]MK-8527 is absorbed by the body, broken down by the body, and how it leaves the body.

Research Team

Medical Director

Principal Investigator

Merck Sharp & Dohme LLC

Eligibility Criteria

This clinical trial is for healthy adults with a BMI between 18 to 32 kg/m2. Participants should be in good overall health without any significant medical conditions.

Inclusion Criteria

I am in good health overall.

My BMI is between 18 and 32.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Treatment

Participants receive a single oral dose of [14C]MK-8527 on Day 1

1 day

1 visit (in-person)

Follow-up

Participants are monitored for absorption, metabolism, and excretion of [14C]MK-8527

5 weeks

Safety Monitoring

Participants are monitored for adverse events and safety outcomes

7 weeks

Treatment Details

Interventions

• MK-8527

Trial Overview [14C]MK-8527 is being tested to understand how it's absorbed, metabolized, and excreted by the body in healthy individuals. This study will track the movement of the drug through the body over time.

Participant Groups

Group I: [14C]MK-8527 Experimental Treatment 1 Intervention

Participants will receive a single oral dose of \[14C\]MK-8527 on Day 1

Who Is Running the Clinical Trial?

Merck Sharp & Dohme LLC

Lead Sponsor

Trials

4,096

Recruited

5,232,000+

Chirfi Guindo

Merck Sharp & Dohme LLC

Chief Marketing Officer since 2022

Degree in Engineering from Ecole Centrale de Paris, MBA from New York University Stern School of Business

Robert M. Davis

Merck Sharp & Dohme LLC

Chief Executive Officer since 2021

JD from Northwestern University Pritzker School of Law, MBA from Northwestern University Kellogg Graduate School of Management, Bachelor's in Finance from Miami University